SynthesisPloS one2012
Meta-analysis on the effects of octreotide on tumor mass in acromegaly.
Synthesis in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2022Pooled it
- Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.The Journal of clinical endocrinology and metabolism · 2014Pooled it
- Expert consensus document: A consensus on the medical treatment of acromegaly.Nature reviews. Endocrinology · 2014Guideline
- Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis.PloS one · 2013Pooled it
- Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study.Pituitary · 2020Trial
- Trial
- Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.The Journal of clinical endocrinology and metabolism · 2014Trial
- Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.Pituitary · 2014Trial
- Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly.Endocrinology · 2026Article
- Reassuring long-term data on efficacy and safety of pegvisomant monotherapy in a large series of patients with acromegaly.Pituitary · 2026Article
- Review
- Consensus on acromegaly therapeutic outcomes: an update.Nature reviews. Endocrinology · 2025Review
- Long-term primary pharmacotherapy of giant prolactinomas: A comparison of different cabergoline dosages.Journal of clinical & translational endocrinology · 2025Article
- The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism.Journal of endocrinological investigation · 2025Article
- Predictors of biochemical and structural response to medical therapy in patients with active acromegaly following surgery: a real-world perspective.BMC endocrine disorders · 2025Article
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).Pituitary · 2024Article
- Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly.TouchREVIEWS in endocrinology · 2024Review
- The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells.International journal of molecular sciences · 2024Article
- Pituitary: hic manebimus optime.Pituitary · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.
objectiveWe performed a meta-analysis to accurately assess the effect of octreotide on pituitary tumor shrinkage. DATA SOURCES: A computerized Medline and Embase search was undertaken to identify potentially eligible studies. STUDY ELIGIBILITY CRITERIA: Eligibility criteria included treatment with octreotide, availability of numerical metrics on tumor shrinkage and clear definition of a clinically relevant reduction in tumor size. Primary endpoints included the proportion of patients with tumor shrinkage and mean percentage reduction in tumor volume. DATA EXTRACTION AND ANALYSIS: The electronic search identified 2202 articles. Of these, 41 studies fulfilling the eligibility criteria were selected for data extraction and analysis. In total, 1685 patients were included, ranging from 6 to 189 patients per trial. For the analysis of the effect of octreotide on pituitary tumor shrinkage a random effect model was used to account for differences in both effect size and sampling error.
resultsOctreotide was shown to induce tumor shrinkage in 53.0% [95% CI: 45.0%-61.0%] of treated patients. In patients treated with the LAR formulation of octreotide, this increased to 66.0%, [95% CI: 57.0%-74.0%). In the nine studies in which tumor shrinkage was quantified, the overall weighted mean percentage reduction in tumor size was 37.4% [95% CI: 22.4%-52.4%], rising to 50.6% [95% CI: 42.7%-58.4%] with octreotide LAR. LIMITATIONS: Most trials examined were open-label and had no control group.
conclusionsOctreotide LAR induces clinically relevant tumor shrinkage in more than half of patients with acromegaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.